Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin

Goulding A, A Goulding, Ailsa Goulding, Gold E, E Gold, Feng W, Wei Feng, W Feng
Bone and mineral · 1992 · vol. 18(2) , pp. 143–152 · doi:10.1016/0169-6009(92)90854-7 · PMID:1525595 · W2090899781
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-11 ⓘ

Tamoxifen treatment in rats effectively prevented bone loss caused by estrogen deficiency induced by the LHRH agonist buserelin.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In young women chronic use of luteinizing hormone releasing hormone (LHRH) agonists such as buserelin to treat endometriosis leads to estrogen-deficiency bone loss. Tamoxifen citrate is an estrogen agonist/antagonist which protects the skeleton from osteopenia when ovarian hormones are depleted. The present study was undertaken to determine whether tamoxifen citrate (20 mg/kg body wt/week s.c.) could prevent the osteopenic effect of buserelin (25 micrograms/kg body wt/day s.c.). Four groups of rats with 45Ca-labelled bones were studied for 4 weeks: group A--placebo controls; group B--buserelin; Group C--tamoxifen; group D--buserelin+tamoxifen. Bone resorption was monitored by measuring the urinary excretion of 45Ca and hydroxyproline. Interestingly buserelin lowered both blood 17 beta-estradiol values and uterine weights in the presence and absence of tamoxifen. However, tamoxifen slowed bone breakdown and inhibited the bone-thinning effects of buserelin. Total body calcium values (mg; means +/- S.D.) were: 2227 +/- 137; 1926 +/- 124; 2233 +/- 94 and 2268 +/- 163, in groups A to D respectively. Osteopenia was thus present only in group B (P less than 0.001). Because tamoxifen inhibits estrogen-deficiency bone loss in buserelin-treated rats without depressing the hypoestrogenic actions of this LHRH-agonist, we suggest that use of tamoxifen to protect the skeleton during LHRH-agonist therapy in young women should be explored. Tamoxifen citrate might also help to prevent postmenopausal osteoporosis.

My notes (saved in your browser only)

MeSH descriptors

Bone Diseases, Metabolic Bone Resorption Buserelin Estrogens Tamoxifen Animals Body Weight Body Weight Bone Diseases, Metabolic Bone Diseases, Metabolic Bone Resorption Bone Resorption Buserelin Buserelin Calcium Calcium Calcium Disease Models, Animal Drug Interactions Estradiol

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (35)

Cited by (2)

Source provenance

europepmc
last seen: 2026-08-04T06:16:37.499272+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:44.647872+00:00
unpaywall
last seen: 2026-08-04T06:56:55.048231+00:00
License: CC0 · commercial use OK